Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Savage

Showing results (281-290 of 375) with videos related to

Pageof 38
Sort By:
JACC. Cardiovascular Interventions|March 29, 2023
Recyclable Waste in the Cardiac Catheterization Laboratory: The Potential to Curb the Carbon FootprintHarsh Doshi, Michael P Savage, Nicholas Ruggiero, et al.
Gastroenterology|February 1, 1986
Peptide YY abnormalities in gastrointestinal diseasesT E Adrian, A P Savage, A J Bacarese-Hamilton, et al.
The American Journal of Cardiology|October 1, 1988
Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factorM P Savage, A S Krolewski, G G Kenien, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1997
Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosisR H Hardwick, C P Barham, P Ozua, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzymeP J Kukkola, P Savage, Y Sakane, et al.
Current Pharmaceutical Design|October 25, 2023
Is Adrenaline Always the First Choice Therapy of Anaphylaxis? An Allergist-cardiologist Interdisciplinary Point of ViewGianfranco Calogiuri, Michael P Savage, Maurizio Congedo, et al.
Life Sciences|August 23, 2000
CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11A J Trapani, S De Lombaert, M E Beil, et al.
Age and Ageing|March 1, 1997
Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatientM B Hogarth, R Gallimore, P Savage, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1986
Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in manT E Adrian, G R Sagor, A P Savage, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066A Y Jeng, S De Lombaert, M E Beil, et al.
Pageof 38

Showing results (281-290 of 375) with videos related to

Sort By:
Pageof 38
JACC. Cardiovascular Interventions|March 29, 2023
Recyclable Waste in the Cardiac Catheterization Laboratory: The Potential to Curb the Carbon FootprintHarsh Doshi, Michael P Savage, Nicholas Ruggiero, et al.
Gastroenterology|February 1, 1986
Peptide YY abnormalities in gastrointestinal diseasesT E Adrian, A P Savage, A J Bacarese-Hamilton, et al.
The American Journal of Cardiology|October 1, 1988
Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factorM P Savage, A S Krolewski, G G Kenien, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1997
Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosisR H Hardwick, C P Barham, P Ozua, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzymeP J Kukkola, P Savage, Y Sakane, et al.
Current Pharmaceutical Design|October 25, 2023
Is Adrenaline Always the First Choice Therapy of Anaphylaxis? An Allergist-cardiologist Interdisciplinary Point of ViewGianfranco Calogiuri, Michael P Savage, Maurizio Congedo, et al.
Life Sciences|August 23, 2000
CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11A J Trapani, S De Lombaert, M E Beil, et al.
Age and Ageing|March 1, 1997
Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatientM B Hogarth, R Gallimore, P Savage, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1986
Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in manT E Adrian, G R Sagor, A P Savage, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066A Y Jeng, S De Lombaert, M E Beil, et al.
Pageof 38